Obseva (NASDAQ:OBSV)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report released on Monday. They currently have a $25.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 127.27% from the stock’s current price.
Other research analysts have also recently issued research reports about the company. Royal Bank of Canada reaffirmed a “buy” rating and issued a $22.00 price target on shares of Obseva in a report on Thursday, November 2nd. Zacks Investment Research raised Obseva from a “sell” rating to a “buy” rating and set a $11.00 price target on the stock in a report on Wednesday, October 18th. BMO Capital Markets began coverage on Obseva in a report on Monday, December 4th. They issued an “outperform” rating and a $20.00 price target on the stock. Finally, Credit Suisse Group began coverage on shares of Obseva in a research note on Monday, October 9th. They set an “outperform” rating and a $16.00 target price on the stock. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $19.00.
Obseva (OBSV) opened at $11.00 on Monday. Obseva has a twelve month low of $5.00 and a twelve month high of $14.69.
Obseva (NASDAQ:OBSV) last posted its quarterly earnings results on Tuesday, November 14th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.01). The business’s quarterly revenue was up NaN% compared to the same quarter last year. sell-side analysts forecast that Obseva will post -2.31 EPS for the current fiscal year.
A number of large investors have recently made changes to their positions in OBSV. Sphera Funds Management LTD. raised its stake in Obseva by 12.4% during the 3rd quarter. Sphera Funds Management LTD. now owns 260,197 shares of the company’s stock valued at $2,118,000 after purchasing an additional 28,700 shares during the period. VHCP Management II LLC raised its stake in Obseva by 834.2% during the 3rd quarter. VHCP Management II LLC now owns 1,401,343 shares of the company’s stock valued at $11,407,000 after purchasing an additional 1,251,343 shares during the period. Abingworth LLP acquired a new stake in Obseva during the 3rd quarter valued at $3,480,000. Iguana Healthcare Management LLC raised its stake in Obseva by 66.7% during the 3rd quarter. Iguana Healthcare Management LLC now owns 50,000 shares of the company’s stock valued at $407,000 after purchasing an additional 20,000 shares during the period. Finally, First Manhattan Co. acquired a new stake in Obseva during the 4th quarter valued at $9,760,000. 38.61% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This story was posted by Stock Observer and is the sole property of of Stock Observer. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.thestockobserver.com/2018/02/05/hc-wainwright-reaffirms-buy-rating-for-obseva-obsv.html.
Obseva Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.